Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
- Financing led by Investissement Québec with continued support from long-standing investors
- Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients
Montreal, Canada – Strasbourg, France – Boston, United States, February 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close of its Series B financing round totaling $32 million CAD. This financing round was led by Investissement Québec and was supported by existing investors CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare BioInnovations, and Seido Capital.
